New combo aims to turn inoperable stomach cancer into a surgical target
NCT ID NCT07194005
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether a combination of three drugs (RC48, sintilimab, and SOX chemotherapy) can shrink advanced stomach cancer enough to allow surgical removal. It enrolls 30 adults aged 18-70 with HER2 1+ or 2+ stomach cancer that cannot be removed initially. Participants receive 4-6 cycles of the drug combo; if the tumor shrinks enough, they undergo surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.